Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens

  • Authors:
    • Teppei Yamada
    • Yasuhiro Terazaki
    • Shinjiro Sakamoto
    • Koichi Yoshiyama
    • Satoko Matsueda
    • Nobukazu Komatsu
    • Kayoko Waki
    • Akira Yamada
    • Akihiko Kawahara
    • Masayoshi Kage
    • Shunichi Sugawara
    • Yuichi Yamashita
    • Tetsuro Sasada
    • Shinzo Takamori
    • Kyogo Itoh
  • View Affiliations

  • Published online on: October 7, 2014     https://doi.org/10.3892/ijo.2014.2699
  • Pages: 55-62
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The prognosis of non-small cell lung cancer (NSCLC) patients who failed two or more treatment regimens remains very poor. We conducted a phase II study to explore the feasibility of personalized peptide vaccination (PPV), in which peptides are selected and administered based on the pre-existing host immunity before vaccination, as a third or more line treatment in advanced NSCLC patients who failed two or more regimens. Among 57 patients enrolled, 23 or 16 patients received PPV with chemotherapy or targeted therapy, respectively, whereas 18 patients received PPV alone. A maximum of four HLA-matched peptides showing higher peptide-specific IgG responses in pre-vaccination plasma were selected from 31 pooled peptide candidates applicable for patients with HLA-A2, -A24, -A3 supertypes, and/or -A26, followed by subcutaneous administration. No severe adverse events related to PPV were observed. Median survival time was 692, 468, or 226 days in the group of PPV/chemotherapy, PPV/targeted therapy, or PPV alone, respectively. CTL responses to the vaccinated peptides became detectable after vaccination in 58, 50, or 42% of patients in each of these three groups, respectively. In contrast, peptide-specific IgG responses after vaccination augmented in 55, 75, or 62% of patients in each of these groups, respectively. These results suggest the feasibility of PPV for heavily treated advanced NSCLC patients from the view of both immunological responses and safety. Therefore, further evaluation of PPV by prospective randomized trial is warranted for a third or fourth line treatment of advanced NSCLC.
View Figures
View References

Related Articles

Journal Cover

January 2015
Volume 46 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yamada, T., Terazaki, Y., Sakamoto, S., Yoshiyama, K., Matsueda, S., Komatsu, N. ... Itoh, K. (2015). Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens. International Journal of Oncology, 46, 55-62. https://doi.org/10.3892/ijo.2014.2699
MLA
Yamada, T., Terazaki, Y., Sakamoto, S., Yoshiyama, K., Matsueda, S., Komatsu, N., Waki, K., Yamada, A., Kawahara, A., Kage, M., Sugawara, S., Yamashita, Y., Sasada, T., Takamori, S., Itoh, K."Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens". International Journal of Oncology 46.1 (2015): 55-62.
Chicago
Yamada, T., Terazaki, Y., Sakamoto, S., Yoshiyama, K., Matsueda, S., Komatsu, N., Waki, K., Yamada, A., Kawahara, A., Kage, M., Sugawara, S., Yamashita, Y., Sasada, T., Takamori, S., Itoh, K."Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens". International Journal of Oncology 46, no. 1 (2015): 55-62. https://doi.org/10.3892/ijo.2014.2699